medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2019, Number 3

Next >>

Rev Mex Patol Clin Med Lab 2019; 66 (3)

Standardization of an in vitro model to evaluate sensitivity of antiparasitaries against Blastocystis spp

Villafaña-Becerra D, Martínez-Méndez L, Dávila-Solís B, Jiménez-Jiménez M, López-Martínez B, Parra-Ortega I

Language: Spanish
References: 32
Page: 132-138
PDF size: 280.00 Kb.


ABSTRACT

Introduction: Blastocystis spp., is an anaerobic, cosmopolitan eukariotic, chromist parasite of the human gut and other species. It is the most frequently reported parasite in coproparasite testing (0.8 to 61.8%). Its pathogenic role it’s still being discussed. The treatment includes antiparasitic drugs such as metronidazol or nitazoxanide. There are few reports about Blastocystis spp. susceptibility aganist metronidazol. Objective: Standarize an in vitro system for evaluating Blastocystis susceptibility aganist antiparasitic drugs, using Barret’s saline-serum culture medium. Material and methods: 30 samples were inoculated in Barret’s saline-serum culture medium, using the following concentrations: 0, 125, 500, 1,250 and 2,500 µg/mL. The parasitic development was determined through viable cell count, in a hemocytometer. The viability was evaluated through exclusion using the colorant eosine 1%, doing lectures at 24, 48 and 72 hours. Results: The development of Blastocystis spp. it was lower for the three concentrations of metronidazole, with respect to the negative control; the least development was observed in the positive control at 24, 48 and 72 hours (p ‹ 0.0001). Conclusions: The proposed methodology allowed us to evaluate the susceptibility of Blastocystis spp. aganist metronidazol, MIC was 125 µg/mL.


REFERENCES

  1. Tasic N, Milenkovic T, Bujic V, Zdravkovic D, Tasic, A. Blastocystis hominis: a misterious and commonly disregarded parasite. Facta Universatis. 2016; 18 (2): 39-47.

  2. Sadaf H, Khan S, Urooj K, Asma B, Ajmal S. Blastocystis hominis-Potencial diahorreal agent: a review. IRJP. 2013; 4 (3): 1-5.

  3. Noel C, Dufernez F, Gerbood D. Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J Clin Microbiol. 2005; 43 (1): 348-355.

  4. del Coco V, Molina N, Basualdo J, Córdoba M. Blastocystis spp.: avances, controversias y desafíos futuros. Rev Argent Microbiol. 2017; 49 (1): 110-118.

  5. Coyle C, Varughese J, Weiss L, Tanowitz H. Blastocystis: to treat or not to treat… Clin Infect Dis. 2012; 54 (1): 105-110.

  6. Ismail S, Ali I, Fahmy Z, Azmy M, Magdy M. Susceptibility of Blastocystis hominis to monolaurine (lauric acid), lactoferine (Lactobacillus acidophillus) and metronidazole: an in vitro and in vivo studies. Afr J Pharm Pharmacol. 2016; 10 (21): 14-25.

  7. Cazorla-Perfetti D. ¿Blastocystis sp. o B. hominis? ¿Protozoario o Chromista? Saber. 2014; 26 (3): 343-346.

  8. Romero J, Martínez L, Romero J. Blastocystis spp.: ¿comensal o patógeno? Rev Enferm Infecc Pediatr. 2018; 30 (123): 1243-1248.

  9. Lepczyńska M, Bialkowska J, Dzika E, Piskorz-Ogórek K, Korycińska J. Blastocystis: how do specific diets and human gut microbiota affect development and pathogenicity? Eur J Clin Microbiol Infect Dis. 2017; 36 (1): 1531-1540.

  10. Rodríguez E, Mateos B, González J, Aguilar Y, Alarcón E, Mendoza A et al. Transición parasitaria a Blastocystis hominis en niños de la zona centro del estado de Guerrero, México. Parasitol Latinoam. 2008; 63: 20-28.

  11. Zapata-Valencia J, Rojas-Cruz C. Una actualización sobre Blastocystis spp. Revista Gastrohnup. 2012; 14 (3): 94-100.

  12. Salgado-López J, Rodríguez-Bataz E. Identificación molecular y análisis filogenético de Blastocystis spp. Tlamati Sabiduria. 2016; 7 (2): 1-10.

  13. Aguirre A. Aportaciones sobre la ultraestructura de Blastocystis hominis. Ensayo bibliográfico. México: Escuela Nacional de Ciencias Biológicas. Instituto Politécnico Nacional; 2003.

  14. Amaya A, Trejo J, Morales E. Blastocystis spp.: revisión literaria de un parásito intestinal altamente prevalente. Rev Univ Ind Santander Salud. 2015; 47 (2): 199-208.

  15. Chandramathi A, Suresh K, Sivanandam S, Kuppusamy U. Stress exacerbates infectivity and pathogenicity of Blastocystis hominis: in vitro and in vivo evidences. PLoS ONE. 2014; 9 (5): e94567. doi: 10.1371/journal.pone.0094567.

  16. Marcos L, Canales M, Terashima A. Blastocystis spp. epidemiology and evidences of its pathogenic role. Rev Peru Parasitol. 2011; 19 (1): 317-325.

  17. Vichido-Luna M, Toro-Monrajaz E, Montijo-Barrios E, Huante-Anaya A, Cervantes-Bustamante R, Ramírez-Mayans J. Blastocystis hominis, un agente patógeno controversial en la génesis de enfermedades gastrointestinales y alérgicas. Alerg Asma Inmunol Pediatr. 2016; 25 (3): 78-83.

  18. Grecu D, Neagu A, Hărmănescu E, Moglan I. In vitro division modalities developed by Blastocystis hominis examined with the acridine orange stain. Analele Științifice ale Universității “Alexandru Ioan Cuza” din Iași, s. Biologie Animală. 2013; 59: 13-17.

  19. Angelov I, Lukanov T, Tsvetkova N, Petkova V, Nicoloff G. Clinical, immunological and parasitological parallels in patients with blastocystosis. J of IMAB. 2008; 1: 55-58.

  20. Boroom K, Smith H, Nimri H, Nimri L, Viscogliosi E, Spanakos G et al. Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection. Parasit Vectors. 2008; 1 (1): 40. doi: 10.1186/1756-3305-1-40.

  21. Tan K. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev. 2008; 21: 639-665.

  22. Tan T, Suresh K, Smith H. Phenotypic and genotypic characterization of Blastocystis hominis isolates implicates subtype 3 as a subtype with pathogenicpotential. Parasitol Res. 2008; 104 (1): 85-93.

  23. Tse SK, Chadee K. Biochemical characterization of rat colonic mucins secreted in response to Entamoeba histolytica. Infect Immun. 1992; 60 (4): 1603-1612.

  24. Charo I, Ransohoff M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354 (6): 610-621.

  25. Fabian I, Kletter Y, Mor S, Geller-Bernstein C, Ben-Yaakov M, Volovitz B et al. Activation of human eosinophil and neutrophil functions by haematopoietic growth factors: comparisons of IL-1, IL-3, IL-5 and GM-CSF. Br J Haematol. 1992; 80 (2): 137-143.

  26. Elwakil H, Hewedi I. Pathogenic potential of Blastocystis hominis in laboratory mice. Parasitol Res. 2010; 107 (3): 685-689.

  27. Sekar U, Shanthi M. Blastocystis consensus of treatment and controversies. Trop Parasitol. 2013; 3 (1): 35-39.

  28. Lepczyńska M, Bialkowska J, Dzika E, Piskorz-Ogórek K, Korycińska J. Blastocystis: how do specific diets and human gut microbiota affect development and pathogenicity? Eur J Clin Microbiol Infect Dis. 2017; 36 (1): 1531-1540.

  29. Salinas J, Vildozola H. Infección por Blastocystis. Rev Gastroenterol Perú. 2007; 27: 264-274.

  30. Eida O, Hussein E, Eida A, El-Moamly, Salem A. Evaluation of the nitric oxide activity against Blastocystis hominis in vitro and in vivo. J Egypt Soc Parasitol. 2008; 38 (2): 521-536.

  31. Batista L, Pérez-Jove J, Rosinach M, Gonzalo V, Saiz E, Loras C et al. Low efficacy of metronidazole in the eradication of Blastocystis hominis in symptomatic patients: case series and systematic literature review. Gastroenterol Hepatol. 2017; 40 (6): 381-387.

  32. Roberts T, Stark D, Harkness J, Ellis J. Update on the pathogenic potential and treatment options for Blastocystis spp. Gut Pathogens. 2014; 6 (7): 1-9.




2020     |     www.medigraphic.com